Department of Biomedical Engineering, Virginia Commonwealth University, Richmond, VA 23284, United States.
Department of Biomedical Engineering, Virginia Commonwealth University, Richmond, VA 23284, United States; Department of Periodontics, University of Texas Health Science Center at San Antonio, San Antonio, TX 78249, United States.
Steroids. 2019 Oct;150:108447. doi: 10.1016/j.steroids.2019.108447. Epub 2019 Jul 11.
Vitamin D has long been prescribed as a supplement to breast cancer patients. This is partially motivated by data indicating that low serum vitamin D, measured as 25-hydroxyvitamin D3 [25(OH)D], is associated with worsened cancer prognosis and decreased survival rates in cancer patients. However, clinical studies investigating the role of vitamin D supplementation in breast cancer treatment are largely inconclusive. One reason for this may be that many of these studies ignore the complexity of the vitamin D metabolome and the effects of these metabolites at the cellular level. Once ingested, vitamin D is metabolized into 37 different metabolites, including 25(OH)D, which is the metabolite actually measured clinically, as well as 1,25(OH)D and 24,25(OH)D. Recent work by our lab and others has demonstrated a role for 24R,25(OH)D, in the modulation of breast cancer tumors via an estrogen receptor α-dependent mechanism. This review highlights the importance of considering estrogen receptor status in vitamin d-associated prognostic studies of breast cancer and proposes a potential mechanism for 24R,25(OH)D signaling in breast cancer cells.
维生素 D 一直被用作乳腺癌患者的补充剂。这部分是由于数据表明，血清中维生素 D 水平低，即 25-羟维生素 D3[25(OH)D]，与癌症患者的预后恶化和生存率降低有关。然而，关于维生素 D 补充剂在乳腺癌治疗中的作用的临床研究结果并不一致。造成这种情况的一个原因可能是，许多研究忽略了维生素 D 代谢组的复杂性以及这些代谢物在细胞水平上的影响。一旦摄入，维生素 D 会代谢成 37 种不同的代谢物，包括 25(OH)D，这是临床上实际测量的代谢物，以及 1,25(OH)D 和 24,25(OH)D。我们实验室和其他实验室的最近的工作表明，24R,25(OH)D 通过雌激素受体 α 依赖性机制在调节乳腺癌肿瘤方面发挥作用。这篇综述强调了在与维生素 D 相关的乳腺癌预后研究中考虑雌激素受体状态的重要性，并提出了 24R,25(OH)D 信号在乳腺癌细胞中的潜在机制。
